Akebia Therapeutics (AKBA) Misses Q3 EPS by 3c

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.46), $0.03 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $92 million versus the consensus estimate of $99.38 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Goldman Regional Director in US Adjusts List of Top Names
• RBC Capital Reiterates Outperform Rating on Eli Lilly (LLY)
• Trump discloses over $1.4 billion in crypto income in 2025 filing